Biopsy devices market seen reaching $3.65 billion by 2035

Market Research Future projects the global biopsy devices market will grow from $2.50 billion in 2026 to $3.65 billion by 2035, driven by cancer screening mandates, AI-guided imaging systems and a shift to outpatient procedures. The forecast points to stronger demand for needle-based instruments, procedure trays and lung biopsy tools as governments expand screening and payors move more biopsies to ambulatory settings.

Why it matters: - Biopsy devices sit at the front end of cancer diagnosis, so higher screening rates and earlier detection directly lift procedure volumes. - The market forecast points to steady demand through 2035, with growth tied more to public policy, reimbursement and workflow automation than to discretionary spending. - The shift from hospital-based procedures to outpatient sites could change purchasing patterns toward single-use kits and pre-packaged trays.

What happened: - Market Research Future said the global biopsy devices market is projected to rise from $2.50 billion in 2026 to $3.65 billion by 2035. - The forecast implies a 4.30% compound annual growth rate from 2026 through 2035. - The market base was estimated at $2.40 billion in 2025. - The release frames government-funded screening mandates and AI-integrated image guidance as the main growth drivers. - The release includes a sample request link: Request a free sample.

The details: - Global cancer incidence is expected to keep expanding the patient pool for tissue confirmation procedures. - The International Agency for Research on Cancer projects 35 million new cancer cases a year by 2050, up 77% from 2022. - Breast, lung and colorectal cancers account for about 38% of that total and rely heavily on biopsy confirmation. - More than 90 countries now have national cancer-control strategies that require pathology-confirmed staging before treatment begins. - Australia launched a bulk-billed low-dose CT lung-screening program in 2025 for high-risk adults ages 50 to 70. - That program is expected to generate about 180,000 additional CT scans a year, with a projected 5% to 8% biopsy conversion rate. - The U.S. Preventive Services Task Force expanded lung-screening eligibility in 2021 to adults with a 20-pack-year history starting at age 50, widening the eligible population by about 6.5 million people. - The European Union’s Beating Cancer Plan is allocating EUR 4 billion across member states. - AI-integrated platforms are replacing freehand needle techniques with image-guided navigation and specimen verification. - These systems are described as cutting procedural time by 30% to 40% and lifting specimen adequacy above 95%. - Real-time specimen verification is reducing non-diagnostic rates from 8% to 12% to under 3%. - Device makers are embedding algorithms in console software, which is raising average selling prices by 15% to 22% per unit. - Medtronic launched an AI-fused stereotactic platform in 2024. - Hologic acquired an automated specimen-verification startup. - Regulator pathways in the U.S. and EU have been streamlined for single-use biopsy instruments. - AI-guided platforms typically require 15 to 25 supervised cases for operator proficiency certification. - Simulation-based training modules can compress the learning curve to under one week. - Ambulatory surgical centers are expanding as Medicare and commercial payors reimburse outpatient breast and thyroid biopsies at rates similar to hospital outpatient departments. - There were about 6,100 U.S. ambulatory surgical centers in 2024, with more than 200 added per year on average. - Medicare’s 2024 ASC-approved CPT code expansion is described as the most consequential near-term catalyst. - Single-use biopsy devices eliminate reprocessing labor and sterilization costs, averaging $12 to $18 per cycle. - In facilities performing more than 500 annual procedures, the total cost of single-use models becomes roughly equivalent to reusable platforms within three years. - China’s county-level hospital upgrade program allocated ¥120 billion to diagnostic equipment procurement in the 14th Five-Year Plan. - India’s Ayushman Bharat scheme funded 182,879 new health-and-wellness centers in early 2026, with 8,000 more targeted through 2028.

Between the lines: - The forecast suggests biopsy demand is becoming more predictable because screening rules and diagnosis pathways are increasingly standardized. - AI guidance appears to be turning biopsy systems into higher-margin hardware-software platforms, not just commodity instruments. - The fastest growth may come from settings that value speed, lower overhead and fewer reprocessing steps, not necessarily from the largest hospitals. - The release also signals that public health spending in Asia-Pacific and Europe is creating more demand than private-sector demand alone could generate.

What's next: - Needle-based biopsy instruments are expected to remain the dominant product category, while procedure trays are the fastest-growing segment. - Breast biopsy will likely remain the largest application, while lung biopsy is projected to grow the fastest. - Ultrasound-guided biopsy remains the dominant technique, while stereotactic biopsy is the fastest-growing guidance method. - Hospitals remain the largest end user, but ambulatory surgical centers are projected to grow the fastest through 2035. - Asia-Pacific is projected to be the fastest-growing region at 8.90% CAGR, led by China and India. - North America remains the largest regional market, with the U.S. accounting for about 78.5% of North American revenue. - By 2030, machine-learning features for lesion segmentation and needle-path planning are expected to become standard on mid-range and premium biopsy consoles. - The release says about 40% of newly diagnosed lung cancer patients could undergo LDCT screening followed by AI-navigated biopsy by 2030. - The full report is available here.